CA2773591A1 - Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs - Google Patents

Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs Download PDF

Info

Publication number
CA2773591A1
CA2773591A1 CA2773591A CA2773591A CA2773591A1 CA 2773591 A1 CA2773591 A1 CA 2773591A1 CA 2773591 A CA2773591 A CA 2773591A CA 2773591 A CA2773591 A CA 2773591A CA 2773591 A1 CA2773591 A1 CA 2773591A1
Authority
CA
Canada
Prior art keywords
methyl
group
trifluoromethyl
oxo
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2773591A
Other languages
English (en)
French (fr)
Inventor
Ulrich Luecking
Arwed Cleve
Bernard Haendler
Hortensia Faus Gimenez
Silke Koehr
Horst Irlbacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CA2773591A1 publication Critical patent/CA2773591A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2773591A 2009-09-11 2010-08-28 Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs Abandoned CA2773591A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP09075421.9 2009-09-11
EP10075069 2010-02-17
EP10075069.4 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
CA2773591A1 true CA2773591A1 (en) 2011-03-17

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773591A Abandoned CA2773591A1 (en) 2009-09-11 2010-08-28 Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs

Country Status (28)

Country Link
US (1) US20120251551A1 (enEXAMPLES)
EP (1) EP2475653A1 (enEXAMPLES)
JP (1) JP2013504523A (enEXAMPLES)
KR (1) KR20120065396A (enEXAMPLES)
CN (1) CN102639523A (enEXAMPLES)
AR (1) AR078166A1 (enEXAMPLES)
AU (1) AU2010294588A1 (enEXAMPLES)
BR (1) BR112012005526A2 (enEXAMPLES)
CA (1) CA2773591A1 (enEXAMPLES)
CL (1) CL2012000623A1 (enEXAMPLES)
CO (1) CO6511228A2 (enEXAMPLES)
CR (1) CR20120113A (enEXAMPLES)
CU (1) CU20120042A7 (enEXAMPLES)
DO (1) DOP2012000063A (enEXAMPLES)
EA (1) EA201200473A1 (enEXAMPLES)
EC (1) ECSP12011716A (enEXAMPLES)
IL (1) IL218390A0 (enEXAMPLES)
IN (1) IN2012DN02081A (enEXAMPLES)
MA (1) MA33566B1 (enEXAMPLES)
MX (1) MX2012002977A (enEXAMPLES)
NZ (1) NZ598643A (enEXAMPLES)
PE (1) PE20121180A1 (enEXAMPLES)
PH (1) PH12012500497A1 (enEXAMPLES)
SG (1) SG178919A1 (enEXAMPLES)
TN (1) TN2012000108A1 (enEXAMPLES)
TW (1) TW201111378A (enEXAMPLES)
UY (1) UY32882A (enEXAMPLES)
WO (1) WO2011029537A1 (enEXAMPLES)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089634A1 (en) * 2013-12-19 2015-06-25 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602089A (en) 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
US9199976B2 (en) * 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR20150014457A (ko) 2012-05-25 2015-02-06 얀센 알 앤드 디 아일랜드 우라실 스피로옥세탄 뉴클레오시드
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
LT2935303T (lt) 2012-12-21 2021-03-25 Janssen Biopharma, Inc. 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
SMT202300014T1 (it) * 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
US10214542B2 (en) 2015-10-08 2019-02-26 Bayer Pharma Aktiengesellschaft Modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
EP3625215B1 (en) 2017-05-18 2023-09-13 PI Industries Ltd Formimidamidine compounds useful against phytopathogenic microorganisms
EA202091894A1 (ru) 2018-02-13 2020-12-28 Байер Акциенгезельшафт Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы
CA3132963A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
WO2021150603A1 (en) * 2020-01-21 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CA2529292A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
ATE427303T1 (de) 2003-09-30 2009-04-15 Janssen Pharmaceutica Nv Benzoimidazolverbindungen
AU2004303602C1 (en) 2003-12-23 2009-05-28 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
ATE503746T1 (de) 2004-08-03 2011-04-15 Chugai Pharmaceutical Co Ltd Neue imidazolidinderivate
CN101048381A (zh) * 2004-09-09 2007-10-03 中外制药株式会社 新型四氢咪唑衍生物及其用途
WO2006058649A1 (en) 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as h3 antagonists
CN101222922B (zh) 2005-05-13 2012-04-18 加利福尼亚大学董事会 二芳基乙内酰脲化合物
AU2007245022A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089634A1 (en) * 2013-12-19 2015-06-25 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EA032467B1 (ru) * 2013-12-19 2019-05-31 Эндорешерш, Инк. Нестероидные антиандрогены и селективные модуляторы андрогеновых рецепторов с пиридильной группой

Also Published As

Publication number Publication date
CU20120042A7 (es) 2012-06-21
ECSP12011716A (es) 2012-04-30
TW201111378A (en) 2011-04-01
KR20120065396A (ko) 2012-06-20
SG178919A1 (en) 2012-04-27
IL218390A0 (en) 2012-04-30
UY32882A (es) 2011-04-29
BR112012005526A2 (pt) 2016-04-26
WO2011029537A1 (en) 2011-03-17
AU2010294588A1 (en) 2012-04-05
EA201200473A1 (ru) 2012-10-30
CR20120113A (es) 2012-05-02
NZ598643A (en) 2013-10-25
AR078166A1 (es) 2011-10-19
EP2475653A1 (en) 2012-07-18
TN2012000108A1 (en) 2013-09-19
CN102639523A (zh) 2012-08-15
JP2013504523A (ja) 2013-02-07
PH12012500497A1 (en) 2012-10-22
MA33566B1 (fr) 2012-09-01
MX2012002977A (es) 2012-04-30
CL2012000623A1 (es) 2012-09-14
PE20121180A1 (es) 2012-08-24
US20120251551A1 (en) 2012-10-04
DOP2012000063A (es) 2012-05-15
CO6511228A2 (es) 2012-08-31
IN2012DN02081A (enEXAMPLES) 2015-08-21

Similar Documents

Publication Publication Date Title
CA2773591A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
CA2772790C (en) Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
AU2011298844B2 (en) Substituted imidazopyridazines
US9555022B2 (en) Substituted triazolopyridines
US8470811B2 (en) Substituted heterocyclylbenzylpyrazoles and use thereof
US20100249085A1 (en) Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US9388140B2 (en) Substituted benzimidazoles
MX2011004779A (es) Compuestos de arilo sustituido y su uso como inhibidores de hif.
CA2832310A1 (en) Substituted imidazopyridines and intermediates thereof
AU2011252222A1 (en) Hydroxyalkyl benzyl pyrazoles, and use thereof for the treatment of hyperproliferative and angiogenic diseases
HK1170732A (en) Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs
DE102008057364A1 (de) Substituierte Aryl-Verbindungen und ihre Verwendung
HK1164851A (en) Heteroaromatic compounds for use as hif inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150828